Controlled-Release AZT Gets FDA Go-Ahead for New Drug Investigation

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

SAN DIEGO--Genta Jago, a joint venture between Genta Incorporated and Jagotec AG (Hergiswil, Switzerland), has filed an Investigational New Drug application with the FDA for a controlled-release formulation of zidovudine (AZT), marketed

SAN DIEGO--Genta Jago, a joint venture between Genta Incorporatedand Jagotec AG (Hergiswil, Switzerland), has filed an InvestigationalNew Drug application with the FDA for a controlled-release formulationof zidovudine (AZT), marketed by Burroughs Wellcome Co. as Retrovir.

The recommended dosage for AZT in the United States is six timesdaily. Results of pilot in vitro and human pharmacokinetic studiesin Europe suggest that once- or twice-daily dosing may be possiblewith the controlled-release formulation, which incorporates Jagotec'sGeomatrix delivery technology.

Related Videos
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the recent approval of nivolumab plus chemotherapy for patients with unresectable or metastatic urothelial carcinoma.
Arvind N. Dasari, MD, MS, an expert on colorectal cancer
A panel of 5 experts on colorectal cancer